Home - Site drug

A highly interdisciplinary consortium of 10 academic and industrial partners in the “2 Seas Region” (Northern France, Southern UK, Northern Belgium and a part of The Netherlands) are working together to develop innovative drug treatments with improved therapeutic efficacies and reduced undesired side effects.

Aim

The aim of this project is to develop innovative drug products, which are able to control the resulting drug distribution in the patient’s body: The drug amount at the site of action is to be optimized, and the amount that is “lost” into the rest of the human body is to be minimized. This is to be achieved by “site-specific delivery systems”, which release the drug at a controlled rate at the site of action. Thus, the therapeutic efficacy will be improved & undesired side effects reduced. This will help reducing the current cost burden on our healthcare systems due to adverse drug effects. Specifically, the project aims at developing innovative site-specific drug delivery systems for the colon, inner ear, peritoneal cavity and breast.

Expected
results

Novel drug products for a safer and more efficient treatment of patients suffering from:
- Crohn’s disease and ulcerative colitis
- Ovarian cancer with metastases in the peritoneal cavity
- Breast resection due to cancer
- Hearing loss/deafness.
A novel in vitro characterization method facilitating the development of “colon targeting systems” and assuring adequate quality control during production.
A feasibility study, demonstrating the performance of the newly developed drug delivery systems.

Funding

This project is funded by the Interreg 2 Seas programme 2014-2020
and the European Regional Development Fund under subsidy contract
“Site Drug 2S07-033”.

Project budget:
4 885 145 €

ERDF amount:
2 931 087 €

ERDF rate:
60%

End Date:
30/03/2023